多組學服務市場－全球產業規模、佔有率、趨勢、機會和預測，按服務、類型、應用、最終用戶、地區和競爭細分，2020-2030 年預測

2024 年全球多組學服務市場價值為 11.6 億美元，預計到 2030 年將達到 30.4 億美元，複合年成長率為 17.39%。隨著醫療保健系統、研究機構和製藥公司擴大採用綜合組學方法來滿足對精準醫療和個人化醫療解決方案日益成長的需求，全球多組學服務市場正在經歷顯著擴張。多組學服務結合了基因組學、轉錄組學、蛋白質組學、代謝組學和表觀基因組學，可以全面了解生物系統和疾病機制。這些方法在藥物發現、生物標記識別和標靶治療開發中變得至關重要。慢性病和遺傳疾病的日益普及、對先進診斷解決方案的需求不斷成長以及學術機構和行業參與者之間的密切合作，正在推動多組學服務的採用。隨著次世代定序、質譜和生物資訊技術的進步，這些服務的效率和可擴展性得到了顯著提高，使其更容易被多個最終用戶部門所使用。

多組學服務市場的成長受到多種因素的推動，包括對精準醫療日益成長的關注、對早期疾病檢測的需求以及組學資料在臨床決策中日益廣泛的應用。製藥和生物技術公司正在利用多組學來簡化藥物開發流程、降低流失率並提高臨床試驗的成功率。先進的生物資訊平台與人工智慧的融合使得資料解讀更加精準，從而在疾病分析和患者分層方面取得了突破。來自政府和私人投資者的策略合作和資金支持正在加速創新並拓展服務格局。此外，伴隨診斷的應用日益普及，這得益於標靶治療的監管批准，進一步催生了對多組學服務的需求，因為這些工具在確定適合特定治療的患者群體方面發揮著核心作用。

儘管成長前景光明，但市場仍面臨可能影響其擴張速度的挑戰。多組學研究的高成本，尤其是在整合多個資料集時，對小型機構和新興經濟體的承受能力構成了擔憂。資料複雜性和互通性問題仍然是重大障礙，因為大規模組學研究會產生大量資料集，需要複雜的分析工具和熟練的專業人員進行解讀。資料隱私方面的擔憂以及實驗室之間缺乏標準化協議，進一步阻礙了多組學的廣泛應用。然而，這些挑戰也為創新創造了機會，因為各公司正在開發更具成本效益的平台、基於雲端的資料解決方案和整合軟體，以簡化分析並提高可擴展性。隨著生物資訊學、人工智慧和自動化技術的不斷進步，市場有望克服其中的許多障礙，為未來幾年多組學在醫療保健和研究領域的廣泛應用鋪平道路。

關鍵市場促進因素

複雜疾病研究日益增多

主要市場挑戰

多組學技術成本高昂

主要市場趨勢

數據整合中的人工智慧和機器學習

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球多組學服務市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按服務（研究服務、數據分析服務）
  • 按類型（單細胞多組學、批量多組學）
  • 按應用（生物標記發現、藥物發現與開發、合成生物學、其他）
  • 按最終用戶（學術和研究機構、製藥和生物技術公司、其他）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美多組學服務市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲多組學服務市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太多組學服務市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲多組學服務市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲多組學服務市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Sapient Bioanalytics, LLC
• Bio-Techne Corporation
• CD Genomics, Inc.
• RayBiotech, Inc.
• Creative Proteomics, Inc.
• Psomagen, Inc.
• Source BioScience Ltd.
• Persistent Systems Ltd.
• Metware Biotechnology Inc.
• Dalton Bioanalytics, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

The Global Multiomics Services Market was valued at USD 1.16 Billion in 2024 and is expected to reach USD 3.04 Billion by 2030 with a CAGR of 17.39%. The Global Multiomics Services Market is experiencing significant expansion as healthcare systems, research institutions, and pharmaceutical companies increasingly adopt integrated omics approaches to address the growing need for precision medicine and personalized healthcare solutions. Multiomics services, which combine genomics, transcriptomics, proteomics, metabolomics, and epigenomics, allow for a comprehensive understanding of biological systems and disease mechanisms. These approaches are becoming critical in drug discovery, biomarker identification, and the development of targeted therapies. The growing prevalence of chronic and genetic diseases, rising demand for advanced diagnostic solutions, and strong collaborations between academic institutions and industry players are pushing the adoption of multiomics services. With technological advancements in next-generation sequencing, mass spectrometry, and bioinformatics, the efficiency and scalability of these services have improved significantly, making them more accessible across multiple end-user sectors.

The growth of the multiomics services market is driven by a combination of factors, including the rising focus on precision healthcare, the need for early disease detection, and the increasing use of omics data in clinical decision-making. Pharmaceutical and biotechnology companies are leveraging multiomics to streamline drug development pipelines, reduce attrition rates, and enhance the success of clinical trials. The integration of advanced bioinformatics platforms and artificial intelligence is enabling more accurate data interpretation, leading to breakthroughs in disease profiling and patient stratification. Strategic collaborations and funding support from governments and private investors are accelerating innovation and expanding the service landscape. In addition, the rising adoption of companion diagnostics, driven by regulatory approval for targeted therapies, is further creating demand for multiomics services, as these tools play a central role in identifying the right patient groups for specific treatments.

Despite the promising growth prospects, the market faces challenges that could impact its pace of expansion. High costs associated with multiomics studies, particularly when integrating multiple datasets, pose affordability concerns for smaller institutions and emerging economies. Data complexity and interoperability issues remain significant hurdles, as large-scale omics studies generate massive datasets requiring sophisticated analytical tools and skilled professionals for interpretation. Concerns over data privacy and the lack of standardized protocols across laboratories further complicate widespread adoption. Nonetheless, these challenges also create opportunities for innovation, as companies are developing more cost-efficient platforms, cloud-based data solutions, and integrated software to simplify analysis and improve scalability. With continuous advancements in bioinformatics, artificial intelligence, and automation, the market is expected to overcome many of these barriers, paving the way for widespread adoption of multiomics in healthcare and research over the coming years.

Key Market Drivers

Growing Research in Complex Diseases

Rising research into complex diseases continues to drive strong momentum in the Global Multiomics Services Market. Conditions such as cancer, neurodegenerative diseases, cardiovascular disorders, autoimmune illnesses, and rare genetic syndromes involve multifaceted biological pathways that cannot be fully described by single-layer analyses. By integrating genomics, transcriptomics, proteomics, epigenomics, and metabolomics, multiomics enables an in-depth view of disease mechanisms, facilitating discovery of novel biomarkers and therapeutic targets. For example, in September 2023 the U.S. National Institutes of Health announced a USD 50.3 million investment over five years to establish the Multi-Omics for Health and Disease Consortium, funding diverse disease studies and scalable workflows for integrating complex datasets. This type of strategic support underscores how critical multiomics has become in tackling intricate health challenges.

Pharmaceutical and biotech firms are turning increasingly to multiomics strategies to bolster drug development efforts in complex disease areas. Heterogeneous patient responses and disease subtypes demand precision; multiomics data helps stratify patient groups, predict outcomes, and optimize clinical trial design. This approach reduces failure rates and accelerates time-to-market for new therapies. Integration with advanced bioinformatics and AI accelerates interpretation of massive datasets, empowering accelerated insights in oncology, neurological disorders, chronic and metabolic conditions. Strong interest among healthcare providers and research organizations in these capabilities continues to bolster demand for multiomics services.

Academic institutions, public-private partnerships, and government agencies worldwide are pouring resources into large-scale multiomics projects focused on elucidating complex disease biology. Availability of funding and infrastructure from agencies such as the NIH helps drive cross-disciplinary collaborations. As healthcare shifts toward predictive, preventive, and personalized paradigms, multiomics research is increasingly central to that transition. The combination of governmental funding, technological advances in high-throughput platforms, and growing pharmaceutical and academic demand ensures that the study of complex diseases will remain one of the most significant long-term drivers for the multiomics services market.

Key Market Challenges

High Cost of Multiomics Technologies

The Global Multiomics Services Market faces a significant challenge in the form of the high cost associated with multiomics technologies, which limits widespread adoption across both research and clinical settings. The integration of genomics, transcriptomics, proteomics, metabolomics, and epigenomics requires highly sophisticated platforms, advanced sequencing technologies, and powerful computational infrastructure capable of handling vast datasets. These resources involve substantial investment in specialized equipment, consumables, and reagents, making multiomics studies cost-prohibitive for many institutions and healthcare providers, especially in resource-constrained environments. Beyond infrastructure, the costs are compounded by the need for skilled professionals who can design experiments, manage complex data pipelines, and perform advanced bioinformatics analysis, often driving up operational expenses.

The expense of large-scale projects becomes even more challenging when multiomics data are applied in clinical research or precision medicine, as validation, regulatory compliance, and data interpretation demand additional financial resources. High costs not only limit accessibility for smaller research institutes and hospitals but also restrict broader patient access to personalized diagnostic and therapeutic solutions that multiomics could enable. This creates a divide between well-funded organizations capable of adopting multiomics and those unable to invest at the required scale, slowing the overall pace of market penetration. Addressing cost-related barriers through technological innovations, more affordable sequencing methods, and scalable cloud-based analytics will be crucial for ensuring that multiomics services can transition from niche applications to mainstream use in global healthcare and life sciences.

Key Market Trends

AI and Machine Learning in Data Integration

The integration of artificial intelligence and machine learning into multiomics services is emerging as a transformative trend, addressing one of the most critical challenges in the field, the complexity and scale of multiomics datasets. Genomic, transcriptomic, proteomic, metabolomic, and epigenomic data generate enormous volumes of information that are difficult to analyze through conventional bioinformatics tools. AI-driven platforms are enabling researchers to uncover hidden patterns, correlate molecular profiles, and predict disease biomarkers with a level of precision and speed that was previously unattainable. Machine learning models are increasingly being applied to classify patient subgroups, identify novel therapeutic targets, and support drug discovery pipelines. The adoption of deep learning techniques allows for the integration of heterogeneous datasets, leading to more comprehensive biological insights and accurate disease modeling.

Pharmaceutical and biotechnology companies are investing in AI-powered analytics to streamline clinical trial design, accelerate target validation, and improve patient stratification for personalized therapies. Cloud-based AI solutions are also gaining prominence, offering scalable infrastructure for large-scale data processing while supporting collaboration across research institutions and healthcare organizations. These innovations are reducing data interpretation bottlenecks, improving reproducibility of results, and making multiomics applications more accessible for both research and clinical use. As AI and machine learning continue to evolve, they are expected to play a pivotal role in shaping the future of multiomics services by enabling more efficient integration, predictive modeling, and translation of omics data into actionable healthcare solutions.

Key Market Players

• Sapient Bioanalytics, LLC
• Bio-Techne Corporation
• CD Genomics, Inc.
• RayBiotech, Inc.
• Creative Proteomics, Inc.
• Psomagen, Inc.
• Source BioScience Ltd.
• Persistent Systems Ltd.
• Metware Biotechnology Inc.
• Dalton Bioanalytics, Inc.

Report Scope:

In this report, the Global Multiomics Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiomics Services Market, By Service:

• Research Services
• Data Analysis Services

Multiomics Services Market, By Type:

• Single-cell Multiomics
• Bulk Multiomics

Multiomics Services Market, By Application:

• Biomarker Discovery
• Drug Discovery & Development
• Synthetic Biology
• Others

Multiomics Services Market, By End User:

• Academic & Research Institutes
• Pharmaceutical and Biotechnology Companies
• Others

Multiomics Services Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiomics Services Market.

Available Customizations:

Global Multiomics Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Multiomics Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Research Services, Data Analysis Services)
  • 5.2.2. By Type (Single-cell Multiomics, Bulk Multiomics)
  • 5.2.3. By Application (Biomarker Discovery, Drug Discovery & Development, Synthetic Biology, Others)
  • 5.2.4. By End User (Academic & Research Institutes, Pharmaceutical and Biotechnology Companies, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Multiomics Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multiomics Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Multiomics Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Multiomics Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Multiomics Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Multiomics Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Multiomics Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Multiomics Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Multiomics Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Multiomics Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Multiomics Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multiomics Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Multiomics Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Multiomics Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Multiomics Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Multiomics Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Multiomics Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multiomics Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Multiomics Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Multiomics Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Multiomics Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multiomics Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Multiomics Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Multiomics Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sapient Bioanalytics, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Bio-Techne Corporation
• 15.3. CD Genomics, Inc.
• 15.4. RayBiotech, Inc.
• 15.5. Creative Proteomics, Inc.
• 15.6. Psomagen, Inc.
• 15.7. Source BioScience Ltd.
• 15.8. Persistent Systems Ltd.
• 15.9. Metware Biotechnology Inc.
• 15.10. Dalton Bioanalytics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer